Clinical Trials: Clinical Trials in USA

Pediatric Clinical Trials and FDA PREA Requirements in the United States

Posted on digi By digi

Sponsors should: (1) submit iPSPs early; (2) design pediatric-friendly formulations; (3) incorporate modeling and extrapolation strategies; (4) enhance safety oversight with pediatric DMCs; (5) engage advocacy groups; (6) use decentralized methods to improve access; (7) harmonize with EMA’s Paediatric Investigation Plans (PIPs); and (8) maintain inspection readiness with robust documentation of consent/assent and safety monitoring.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

The Role of NIH in Funding Clinical Trials in the United States

Posted on digi By digi

Investigators should: (1) align proposals with NIH priorities; (2) prepare robust inclusion and diversity plans; (3) ensure compliance with GCP, ClinicalTrials.gov, and data sharing requirements; (4) establish strong institutional support; (5) leverage CTSA hubs; (6) maintain transparent budgets; (7) engage community stakeholders; (8) harmonize with FDA regulatory requirements; and (9) seek NIH program officer guidance early in the application process.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Clinical Trial Transparency and ClinicalTrials.gov Requirements in the United States

Posted on digi By digi

Sponsors should: (1) establish SOPs for registration and reporting; (2) train staff in ClinicalTrials.gov processes; (3) use centralized institutional offices to manage submissions; (4) monitor deadlines and set automated reminders; (5) prepare results templates in advance; (6) ensure consistency between protocols, publications, and registry entries; (7) engage compliance officers to audit submissions; and (8) maintain records in the Trial Master File (TMF).

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Informed Consent Regulations in the United States: FDA and OHRP Requirements for Clinical Trials

Posted on digi By digi

Sponsors and investigators should: (1) implement robust version control systems; (2) use lay-friendly language; (3) incorporate multimedia for complex trials; (4) train staff rigorously; (5) integrate HIPAA authorizations seamlessly; (6) maintain participant copies; (7) document re-consent when risks change; (8) conduct mock audits for consent forms; (9) engage IRBs early for novel approaches; and (10) ensure inspection readiness at all times.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Diversity and Inclusion in U.S. Clinical Trial Recruitment: FDA and NIH Expectations

Posted on digi By digi

Sponsors should: (1) submit FDA diversity plans early; (2) leverage decentralized models; (3) provide logistical and financial support; (4) translate and adapt materials; (5) engage community organizations; (6) diversify site selection; (7) track progress with real-time dashboards; (8) train investigators in cultural competency; (9) integrate patient input into recruitment strategies; and (10) maintain transparency in demographic reporting.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

FDA Bioresearch Monitoring (BIMO) Inspections in U.S. Clinical Trials: What Sponsors Should Expect

Posted on digi By digi

Sponsors and investigators should: (1) maintain inspection readiness at all times; (2) implement comprehensive SOPs; (3) train staff on GCP and FDA expectations; (4) conduct internal audits and mock inspections; (5) establish robust CAPA systems; (6) document oversight of CROs and vendors; (7) validate electronic systems for Part 11 compliance; (8) ensure timely adverse event reporting; (9) maintain accurate delegation and training logs; and (10) engage compliance officers in inspection preparation.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

IND Safety Reporting Requirements in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) implement robust pharmacovigilance systems; (2) establish clear SOPs for SUSAR reporting; (3) train investigators and staff; (4) use independent DMCs; (5) harmonize global reporting rules; (6) validate electronic reporting systems; (7) monitor vendor compliance; (8) maintain real-time safety databases; (9) audit safety processes; and (10) conduct periodic CAPA reviews.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Clinical Trial Insurance and Liability Coverage in the United States

Posted on digi By digi

Sponsors should: (1) maintain robust subject injury coverage; (2) include indemnification clauses in CTAs; (3) harmonize insurance across states and sites; (4) engage IRBs early for subject injury statement approval; (5) verify investigator malpractice policies; (6) ensure CROs maintain adequate insurance; (7) review policies annually; (8) align coverage with global trial requirements; and (9) train site staff on how to explain subject injury protections to participants.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Phase 3 Global Clinical Trials Anchored in the United States

Posted on digi By digi

Sponsors should: (1) anchor pivotal Phase 3 trials in the U.S. to align with FDA expectations; (2) submit diversity plans early; (3) harmonize trial designs with ICH E17; (4) establish strong global site networks; (5) implement robust vendor and CRO oversight; (6) maintain continuous inspection readiness; (7) engage DMCs early; (8) standardize electronic data systems; and (9) plan for simultaneous global submissions.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Real-World Data Integration in U.S. Clinical Submissions

Posted on digi By digi

Sponsors should: (1) align early with FDA on RWD use; (2) ensure data traceability and validation; (3) adopt CDISC standards; (4) combine RWD with RCTs for stronger evidence; (5) establish SOPs for RWD governance; (6) engage IRBs and ethics boards for RWD studies; (7) integrate patient and physician input; (8) validate digital tools; (9) address confounding with robust statistical methods; and (10) prepare for FDA inspections with complete documentation.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials